Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 852Neoplasms 643Prostatic Neoplasms 439Lung Neoplasms 359Colorectal Neoplasms 327Carcinoma, Non-Small-Cell Lung 318Leukemia, Myeloid, Acute 251Pancreatic Neoplasms 218Brain Neoplasms 202Multiple Myeloma 198Neoplasm Metastasis 191Carcinoma, Hepatocellular 178Head and Neck Neoplasms 176Glioblastoma 167Precursor Cell Lymphoblastic Leukemia-Lymphoma 166Melanoma 153Ovarian Neoplasms 149Squamous Cell Carcinoma of Head and Neck 148Rectal Neoplasms 134Recurrence 132Hematologic Neoplasms 125Sarcoma 124Uterine Cervical Neoplasms 117Stomach Neoplasms 116Carcinoma, Renal Cell 115Triple Negative Breast Neoplasms 114Glioma 114Motor Activity 100Myelodysplastic Syndromes 96Esophageal Neoplasms 96

Interventions

defactinib 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Advanced Colorectal Cancer × 90 days × Clear all
NCT06369259 2026-05-20

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

M.D. Anderson Cancer Center

Phase 2 Recruiting
33 enrolled
Gastrointestinal

Advanced Colorectal Cancer

NCT07558083 2026-04-30

FOLICOLOR

University Hospital, Antwerp

Phase 3 Recruiting
150 enrolled
Gastrointestinal

Advanced Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡